376817
1-(2,3,5,6-Tetrafluorophenyl)imidazole
99%
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C9H4F4N2
CAS Number:
Molecular Weight:
216.14
MDL number:
UNSPSC Code:
12352100
PubChem Substance ID:
Assay
99%
mp
92-94 °C (lit.)
SMILES string
Fc1cc(F)c(F)c(c1F)-n2ccnc2
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Xiaodong Zhang et al.
Anticancer research, 29(4), 1443-1448 (2009-05-06)
Most cancer cells exhibit increased anaerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to the secretion of lactic acid even in the presence of
Saroj P Mathupala et al.
Seminars in cancer biology, 19(1), 17-24 (2008-12-23)
The most common metabolic hallmark of malignant tumors, i.e., the "Warburg effect" is their propensity to metabolize glucose to lactic acid at a high rate even in the presence of oxygen. The pivotal player in this frequent cancer phenotype is
Esther Hulleman et al.
Blood, 113(9), 2014-2021 (2008-11-04)
Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone). Recently, we demonstrated that genes associated with glucose metabolism are differentially expressed between prednisolone-sensitive and prednisolone-resistant precursor B-lineage leukemic patients. Here, we show
Ji Su Kim et al.
Journal of bioenergetics and biomembranes, 40(6), 607-618 (2008-12-11)
Hexokinase type II (HK II) is the key enzyme for maintaining increased glycolysis in cancer cells where it is overexpressed. 3-bromopyruvate (3-BrPA), an inhibitor of HK II, induces cell death in cancer cells. To elucidate the molecular mechanism of 3-BrPA-induced
Axel-R Hanauske et al.
Investigational new drugs, 27(4), 356-365 (2008-10-29)
The objectives of this phase I study were to determine the maximum tolerated dose (MTD), recommended phase II dose (RD), antitumor activity, safety, and pharmacokinetics of pemetrexed-paclitaxel combination. Patients (N = 95) with advanced solid tumors were assigned to three
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service